

Sun Pharmaceutical Industries Ltd.,  
SUN HOUSE, CTS No. 201 B/1,  
Western Express HI Highway, Goregaon(E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
CIN: L24230GJ1993PLC019050  
www.sunpharma.com



**8 December 2022.**

National Stock Exchange of India Ltd,  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai – 400 051.

BSE Limited,  
Market Operations Dept.  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.

Dear Sirs,

**Sub: Update on Halol facility - Additional details**

In furtherance of our communication dated today, December 8, 2022 regarding USFDA Import Alert at Halol facility, we wish to share additional details on the same in the form of Q&A, as attached herewith.

This is for your information and further dissemination.

Thanking you,

Yours faithfully,  
For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary & Compliance Officer**

## **Q&A: USFDA Import Alert at Halol facility**

### **1. Is Sun Pharma revising its FY23 revenue guidance downwards due to Import Alert at Halol?**

US supplies from Halol contributed approximately 3% of consolidated revenues for the year ended 31<sup>st</sup> March 2022, including sales from exempted products. We are not revising our revenue guidance for the current financial year.

### **2. Will there be any impact on sales of Sun Pharma's specialty portfolio?**

There will be no impact on our specialty revenues.

### **3. What are the back-up facilities available for key products currently made at Halol?**

Site transfer of all products manufactured at Halol would be a complex and time-consuming process, considering that other manufacturing facilities may not have similar infrastructure. Hence, we would evaluate product transfers on a case-to-case basis.

### **4. What is the revenue contribution from 14 exempted products?**

Halol's contribution of approximately 3%, stated above, includes the revenues from these exempted products.

### **5. What are the conditions required by USFDA for supply of 14 exempted products?**

The conditions for the supplies of 14 exempted products are confidential.

### **6. Will Sun Pharma be incurring additional costs for meeting conditions for supply of 14 exempted products?**

We are assessing the incremental costs to meet conditions for supply of these products. However, we believe that the same will not be material.

### **7. What would be additional costs of remediation at Halol facility, following the import alert. Will you be appointing external consultants?**

We are currently evaluating if any additional costs need to be incurred. If there is a material change, we will disclose accordingly.

**8. What would be the impact of Import Alert on revenues next year?**

Our revenue guidance for next year, as and when shared, shall incorporate the same.

**9. Will supplies to other markets get impacted due to Import Alert at Halol?**

We don't have any information presently.

**10. How much time will be required to get Halol back into full compliance?**

We are working with the USFDA and will undertake all necessary steps to resolve these issues. At this point in time, we are unable to provide a timeline for resolution.

**Disclaimer:**

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.